Nichi-Iko Pharmaceutical Co., Ltd.
Nichi-Iko Pharmaceutical Co., Ltd. Fundamental Analysis
Nichi-Iko Pharmaceutical Co., Ltd. (4541.T) shows moderate financial fundamentals with a PE ratio of 0.27, profit margin of 3.85%, and ROE of 12.93%. The company generates $234.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 72.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 4541.T's fundamental strength across five key dimensions:
Efficiency Score
Weak4541.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent4541.T trades at attractive valuation levels.
Growth Score
Weak4541.T faces weak or negative growth trends.
Financial Health Score
Excellent4541.T maintains a strong and stable balance sheet.
Profitability Score
Weak4541.T struggles to sustain strong margins.
Key Financial Metrics
Is 4541.T Expensive or Cheap?
P/E Ratio
4541.T trades at 0.27 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 4541.T's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Nichi-Iko Pharmaceutical Co., Ltd. at 0.02 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 1.79 times EBITDA. This is generally considered low.
How Well Does 4541.T Make Money?
Net Profit Margin
For every $100 in sales, Nichi-Iko Pharmaceutical Co., Ltd. keeps $3.85 as profit after all expenses.
Operating Margin
Core operations generate 4.62 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.93 in profit for every $100 of shareholder equity.
ROA
Nichi-Iko Pharmaceutical Co., Ltd. generates $2.64 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Nichi-Iko Pharmaceutical Co., Ltd. produces operating cash flow of $29.47B, showing steady but balanced cash generation.
Free Cash Flow
Nichi-Iko Pharmaceutical Co., Ltd. produces free cash flow of $22.89B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $325.01 in free cash annually.
FCF Yield
4541.T converts 670.93% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.27
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.003
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.02
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.44
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How 4541.T Stacks Against Its Sector Peers
| Metric | 4541.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.27 | 28.25 | Better (Cheaper) |
| ROE | 12.93% | 780.00% | Weak |
| Net Margin | 3.85% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 1.44 | 4.66 | Neutral |
| ROA | 2.64% | -14687.00% (disorted) | Weak |
4541.T outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nichi-Iko Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation